{"id":634359,"date":"2023-01-17T16:26:01","date_gmt":"2023-01-17T16:26:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=634359"},"modified":"2023-01-17T16:26:01","modified_gmt":"2023-01-17T16:26:01","slug":"acute-pain-market-to-witness-upsurge-in-growth-during-the-forecast-period-20222032-examines-delveinsight-key-companies-charleston-laboratories-neumentum-neurana-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/acute-pain-market-to-witness-upsurge-in-growth-during-the-forecast-period-20222032-examines-delveinsight-key-companies-charleston-laboratories-neumentum-neurana-pharmaceuticals_634359.html","title":{"rendered":"Acute Pain Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examines DelveInsight | Key Companies &#8211; Charleston Laboratories, Neumentum, Neurana Pharmaceuticals"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1673946611.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Acute Pain Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examines DelveInsight | Key Companies - Charleston Laboratories, Neumentum, Neurana Pharmaceuticals\" src=\"https:\/\/www.abnewswire.com\/uploads\/1673946611.jpeg\" alt=\"Acute Pain Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examines DelveInsight | Key Companies - Charleston Laboratories, Neumentum, Neurana Pharmaceuticals\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The Acute Pain market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acute Pain pipeline products will significantly revolutionize the Acute Pain market dynamics.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <strong>&ldquo;Acute Pain Market Insights, Epidemiology, and Market Forecast-2032&Prime;<\/strong> report offers an in-depth understanding of the Acute Pain, historical and forecasted epidemiology as well as the Acute Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The Acute Pain market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current &amp; forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, market drivers &amp; barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To Know in detail about the Acute Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/acute-pain-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Acute Pain Market Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Acute Pain Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Acute pain is defined as &ldquo;an expected physiologic experience of injurious stimuli that can become pathologic, is normally sudden in onset, time-limited, and motivates behaviors to avoid actual or potential tissue injuries.&rdquo; The presence of pain often means that something is wrong. Each individual is the best judge of his or her own pain.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Acute Pain Market Report:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Acute Pain market size is anticipated to grow with a significant <strong>CAGR<\/strong> during the study period (2019-2032)<\/li>\n<li>DelveInsight&rsquo;s epidemiology model for acute pain has assessed the total patient pool with Acute Pain, based on the proportion of population undergoing surgery, trauma injury, and other medical illness, respectively. We have assessed that the patient pool of acute pain in the US was nearly <strong>91,727,250<\/strong> in 2021<\/li>\n<li><strong>Key Acute Pain Companies:<\/strong> Charleston Laboratories, Neumentum, Neurana Pharmaceuticals, and others<\/li>\n<li><strong>Key Acute Pain Therapies:<\/strong> CL-108, NTM-001, Omzya, and others<\/li>\n<li>The Acute Pain epidemiology based on gender analyzed that in the United States, out of the total acute pain cases approximately 38%, 47%, and 15% cases are mild, moderate and severe, respectively<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free sample for the Acute Pain Market Report &#8211;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acute-pain-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/sample-request\/acute-pain-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key benefits of the Acute Pain Market report:<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Acute Pain market report covers a descriptive overview and comprehensive insight of the Acute Pain Epidemiology and Acute Pain market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) &amp; Japan.)<\/li>\n<li>The Acute Pain market report provides insights on the current and emerging therapies.<\/li>\n<li>Acute Pain market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/li>\n<li>The Acute Pain market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Acute Pain market.<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Acute Pain epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acute-pain-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Acute Pain Epidemiological Insights<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Acute Pain Market<\/strong> &nbsp;<\/p>\n<p style=\"text-align: justify;\">The dynamics of the Acute Pain market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><em>&ldquo;Of the emerging therapies, one of the most anticipated product to get approved is CL-108. Apart from this, several other molecules are in mid to late stage of clinical development currently&rdquo;<\/em><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Acute Pain Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Acute Pain Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Acute Pain market report proffers epidemiological analysis for the study period 2019&ndash;2032 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Prevalence of Acute Pain<\/li>\n<li>Prevalent Cases of Acute Pain by severity<\/li>\n<li>Gender-specific Prevalence of Acute Pain<\/li>\n<li>Diagnosed Cases of Episodic and Chronic Acute Pain<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Acute Pain Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Pain market or expected to get launched during the study period. The analysis covers Acute Pain market uptake by drugs, patient uptake by therapies, and sales of each drug.&nbsp;<\/p>\n<p style=\"text-align: justify;\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\">The report also covers the Acute Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major Acute Pain market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acute-pain-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Acute Pain market forecast<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Acute Pain Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>CL-108:<\/strong> Charleston Laboratories<\/li>\n<li><strong>NTM-001:<\/strong> Neumentum<\/li>\n<li><strong>Omzya:<\/strong> Neurana Pharmaceuticals<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Acute Pain Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Increasing diagnosed prevalence of acute pain<\/li>\n<li>Emergence in novel treatment target<\/li>\n<li>Less competition among therapies<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Acute Pain Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Study Period: 2019&ndash;2032<\/strong><\/li>\n<li><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/li>\n<li><strong>Key Acute Pain Companies:<\/strong> Charleston Laboratories, Neumentum, Neurana Pharmaceuticals, and others<\/li>\n<li><strong>Key Acute Pain Therapies:<\/strong> CL-108, NTM-001, Omzya, and others<\/li>\n<li><strong>Acute Pain Therapeutic Assessment:<\/strong> Acute Pain current marketed and Acute Pain emerging therapies<\/li>\n<li><strong>Acute Pain Market Dynamics:<\/strong>&nbsp;Acute Pain market drivers and Acute Pain market barriers&nbsp;<\/li>\n<li><strong>Competitive Intelligence Analysis:<\/strong> SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/li>\n<li><strong>Acute Pain Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Acute Pain Market Access and Reimbursement&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Acute Pain Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Adverse events associated with the current therapies<\/li>\n<li>The pipeline not very robust<\/li>\n<li>Disease burden<\/li>\n<li>Challenges in the diagnosis of disease<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Acute Pain Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary for Acute Pain<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis of Acute Pain<\/p>\n<p style=\"text-align: justify;\">4. Acute Pain Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Acute Pain Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Acute Pain Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Acute Pain Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Acute Pain&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. Acute Pain Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Acute Pain Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Acute Pain Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Acute Pain Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Acute Pain Market Analysis (2019&ndash;2032)<\/p>\n<p style=\"text-align: justify;\">14. Acute Pain Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Acute Pain Market Drivers<\/p>\n<p style=\"text-align: justify;\">16. Acute Pain Market Barriers<\/p>\n<p style=\"text-align: justify;\">17.&nbsp; Acute Pain Appendix<\/p>\n<p style=\"text-align: justify;\">18. Acute Pain Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Acute Pain treatment, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acute-pain-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Acute Pain Medications<\/a> <\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=acute-pain-market-to-witness-upsurge-in-growth-during-the-forecast-period-20222032-examines-delveinsight-key-companies-charleston-laboratories-neumentum-neurana-pharmaceuticals\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=acute-pain-market-to-witness-upsurge-in-growth-during-the-forecast-period-20222032-examines-delveinsight-key-companies-charleston-laboratories-neumentum-neurana-pharmaceuticals\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Acute Pain market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acute Pain pipeline products will significantly revolutionize the Acute Pain market dynamics. DelveInsight&rsquo;s &ldquo;Acute Pain Market &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/acute-pain-market-to-witness-upsurge-in-growth-during-the-forecast-period-20222032-examines-delveinsight-key-companies-charleston-laboratories-neumentum-neurana-pharmaceuticals_634359.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-634359","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/634359","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=634359"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/634359\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=634359"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=634359"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=634359"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}